Great. This means Merck's Keytruda and Bristol Me
Post# of 157598
(Total Views: 546)
Posted On: 09/30/2025 7:14:09 AM
Great. This means Merck's Keytruda and Bristol Meyers' Opdivo can't be used in esophageal cancers.... unless...
Yes, how can we get immunotherapies to be effective in cancers that have low PD-L1 expression? How in the world could we raise PD-L1 expression in solid-tumor cancers?
Psst. Hey, Merck. Hey, BMS. Got a minute?
Quote:
Changes to both drug labels come amid growing evidence that patients with low or no PD-L1 expression derive limited benefit from these agents...
“I really hope we can see how this evolves and how we can get immunotherapies to be effective in this PD-L1-negative population,” said ODAC member Hanna K. Sanoff, MD, MPH, during the September ODAC meeting. “Until we do that, I just did not see enough evidence that we’re helping people and not harming them.”
Yes, how can we get immunotherapies to be effective in cancers that have low PD-L1 expression? How in the world could we raise PD-L1 expression in solid-tumor cancers?
Psst. Hey, Merck. Hey, BMS. Got a minute?
(20)
(0)